Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
1743studies shown
Showing 193-204 of 1,743
Drug study icon
CompletedNCT06432322

(GluEsk) Glutamate and Esketamine

This summary needs review. Please check the official study record and contact the research team for details.

In United Kingdom
DepressionDrugA study involving a medication or substance.From 18 Years to 50 Years
Countries
United Kingdom
Sponsor
University of Oxford
Condition
Depression
Drug study icon
CompletedEUCTR 2008-002247-16

A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
SchizophreniaDrug
Countries
France, United Kingdom, Belgium, ...
Sponsor
Janssen-Cilag International N.V.
Condition
Schizophrenia
Drug study icon
CompletedNCT01714713

EVP-6124 (Alpha-7 nAChR) for schizophrenia

This study is completed in the United States, in Australia, in Canada, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.

In United Kingdom
SchizophreniaDrugFrom 18 Years to 50 Years
Countries
United States, Australia, Canada, ...
Sponsor
FORUM Pharmaceuticals Inc
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2012-002785-12

A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
SchizophreniaDrug
Countries
United Kingdom, Czechia, Estonia, ...
Sponsor
H. Lundbeck A/S
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2015-004835-10

A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients with Schizophrenia Previously Stabilized on the Pa...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
SchizophreniaDrug
Countries
United Kingdom, Croatia, Denmark, ...
Sponsor
Janssen-Cilag International NV
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2013-001695-38

A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
SchizophreniaDrugFrom 13 Years to 17 Years
Countries
United States, France, United Kingdom, ...
Sponsor
SUNOVION PHARMACEUTICALS INC.
Condition
Schizophrenia
Drug study icon
TerminatedNCT07329621

Binding of MSP-2020 to Serotonin 5-HT2A Receptors for Depression

This study was terminated in the United Kingdom. It is testing Binding of MSP-2020 to Serotonin 5-HT2A Receptors for Depression.

In United Kingdom
DepressionDrugFrom 23 Years to 55 Years
Countries
United Kingdom
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Depression
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.